FDG-PET reveals improved cardiac regeneration and attenuated adverse remodelling following Sitagliptin + G-CSF therapy after acute myocardial infarction
Author(s) -
Lisa Groß,
Lisa Paintmayer,
Sebastian Lehner,
Lydia Brandl,
Christoph Brenner,
Ulrich Grabmaier,
Bruno Hüber,
Peter Bartenstein,
Hans-Diogenes Theiss,
WolfgangMichael Franz,
Steffen Maßberg,
Andrei Todica,
Stefan Brunner
Publication year - 2015
Publication title -
european heart journal - cardiovascular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.576
H-Index - 92
eISSN - 2047-2412
pISSN - 2047-2404
DOI - 10.1093/ehjci/jev237
Subject(s) - myocardial infarction , medicine , sitagliptin , bone marrow , ligation , cardiology , placebo , ventricular remodeling , ejection fraction , heart failure , pathology , insulin , alternative medicine , metformin
Dual therapy comprising G-CSF for mobilization of bone marrow-derived progenitor cells (BMPCs), with simultaneous pharmacological inhibition of dipeptidylpeptidase-IV for enhanced myocardial recruitment of circulating BMPC via the SDF-1α/CXCR4-axis, has been shown to improve survival after acute myocardial infarction (AMI). Using an innovative method to provide non-invasive serial in vivo measurements and information on metabolic processes, we aimed to substantiate the possible effects of this therapeutic concept on cardiac remodelling after AMI using 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography (FDG-PET).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom